Skip to main content
Top
Published in: Annals of Hematology 9/2019

01-09-2019 | Hemolytic Anemia | Letter to the Editor

Hb Fairfax [HBB:c.285_286insGAGCTGCACTGTGAC] in a Brazilian patient with severe hemolytic anemia—identification and functional study

Authors: S. E. Jorge, C. Lanaro, D. M. Albuquerque, P. H. Nascimento, G. A. Pedroso, S. C. Oliveira, M. R. P. Grigoleto, M. N. N. Santos, F. F. Costa, M. F. Sonati

Published in: Annals of Hematology | Issue 9/2019

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Greenberg J, Fairbanks VF, Hoyer J, Thibodeau SN, Fairfax VA (1997) Hemoglobin Fairfax, a tandem duplication of β90–94 inserted between β94–β95 (proved by DNA sequence analysis): a previously undescribed unstable hemoglobin variant associated with severe hemolytic anemia and stroke during early childhood [abstract]. Blood 90(Suppl. 1):27B Greenberg J, Fairbanks VF, Hoyer J, Thibodeau SN, Fairfax VA (1997) Hemoglobin Fairfax, a tandem duplication of β90–94 inserted between β94–β95 (proved by DNA sequence analysis): a previously undescribed unstable hemoglobin variant associated with severe hemolytic anemia and stroke during early childhood [abstract]. Blood 90(Suppl. 1):27B
4.
go back to reference Dacie JV, Lewis SM (1995) Practical haematology, 8th edn. Churchill Livingstone, New York Dacie JV, Lewis SM (1995) Practical haematology, 8th edn. Churchill Livingstone, New York
6.
go back to reference Hartelveld CL, Thelen MH, Rutten JJ, Leuverman J, Akkermans N, van Delft P, Arlesteijn S, Giordano PC (2005) HbGeldrop St Anna [beta94(FG1)Asp-->Tyr]: a new hemoglobin variant observed in a diabetic patient. Hemoglobin 29(2):107–112 Hartelveld CL, Thelen MH, Rutten JJ, Leuverman J, Akkermans N, van Delft P, Arlesteijn S, Giordano PC (2005) HbGeldrop St Anna [beta94(FG1)Asp-->Tyr]: a new hemoglobin variant observed in a diabetic patient. Hemoglobin 29(2):107–112
7.
go back to reference Como PF, Kennett D, Wilkinson T, Kronenberg H (1983) A new hemoglobin with high oxygen affinity - hemoglobin Bunbury: alpha 2 beta 2 [94 (FG1) Asp replaced by Asn]. Hemoglobin 7(5):413–421CrossRefPubMed Como PF, Kennett D, Wilkinson T, Kronenberg H (1983) A new hemoglobin with high oxygen affinity - hemoglobin Bunbury: alpha 2 beta 2 [94 (FG1) Asp replaced by Asn]. Hemoglobin 7(5):413–421CrossRefPubMed
8.
go back to reference Wajcman H, Aguilar I Bascompete JL, Labie D, Poyart C, Bohn B (1982) Structural and functional studies of hemoglobin Barcelona (alpha 2 beta 2 94 Asp (FG1) replaced by His). Consequences of altering an important intra chain salt bridge involved in the alkaline Bohr effect. J Mol Biol 156(1):185–202CrossRefPubMed Wajcman H, Aguilar I Bascompete JL, Labie D, Poyart C, Bohn B (1982) Structural and functional studies of hemoglobin Barcelona (alpha 2 beta 2 94 Asp (FG1) replaced by His). Consequences of altering an important intra chain salt bridge involved in the alkaline Bohr effect. J Mol Biol 156(1):185–202CrossRefPubMed
9.
go back to reference Dash S, Das R (2004) Late emergence of polycythemia in a case of Hb Chandigarh [beta94(FG1)Asp-->Gly]. Hemoglobin 28(3):273–274CrossRefPubMed Dash S, Das R (2004) Late emergence of polycythemia in a case of Hb Chandigarh [beta94(FG1)Asp-->Gly]. Hemoglobin 28(3):273–274CrossRefPubMed
Metadata
Title
Hb Fairfax [HBB:c.285_286insGAGCTGCACTGTGAC] in a Brazilian patient with severe hemolytic anemia—identification and functional study
Authors
S. E. Jorge
C. Lanaro
D. M. Albuquerque
P. H. Nascimento
G. A. Pedroso
S. C. Oliveira
M. R. P. Grigoleto
M. N. N. Santos
F. F. Costa
M. F. Sonati
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03728-5

Other articles of this Issue 9/2019

Annals of Hematology 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.